文献速递乳腺癌支持与姑息治疗

改善乳腺癌放疗急性毒性患者体验:大型多中心队列患者报告结局分析

Toward Improving Patients' Experiences of Acute Toxicity From Breast Radiotherapy: Insights From the Analysis of Patient-Reported Outcomes in a Large Multicenter Cohort.
PubMed 文献 · J Clin Oncol · 2020-09-28

该研究前瞻性分析了8711例2012至2019年间在27家机构接受全乳放疗的乳腺癌患者报告结局。大分割放疗较常规分割放疗的中重度乳腺疼痛、频繁症状困扰和严重疲劳报告率均更低;年轻、高BMI、黑人或其他种族、吸烟、较大乳房体积等因素与乳腺疼痛相关。

要点

  • 大分割放疗较常规分割放疗的中重度乳腺疼痛报告率更低(28.9% vs 45.7%)。
  • 大分割放疗的频繁症状困扰报告率为41.3%,低于常规分割的60.7%。
  • 年轻、高BMI、吸烟、较大乳房体积等与放疗后乳腺疼痛相关。

核心结论

  • 在该大型观察数据集中,放疗剂量分割方式间存在实质性差异。
  • 尽管控制了多个其他因素,疼痛的种族差异仍然存在,需进一步研究可干预因素。
  • 对识别出的易感亚组加强支持治疗可能是合适的。

研究设计与样本

  • 前瞻性收集患者报告结局的观察性队列研究,纳入8711例2012至2019年在27家机构接受全乳放疗的乳腺癌患者。
  • 采用多变量模型识别与乳腺疼痛、治疗侧乳房症状困扰及疲劳相关的特征。

主要发现

  • 3233例(37.1%)报告中度或重度乳腺疼痛,其中大分割组1282例(28.9%),常规分割组1951例(45.7%)。
  • 4424例(50.8%)报告至少一种乳房症状的频繁困扰,其中大分割组1833例(41.3%),常规分割组2591例(60.7%)。
  • 2008例(23.1%)报告严重疲劳,其中大分割组843例(19.0%),常规分割组1165例(27.3%)。
  • 大分割组中,年轻年龄(P < .001)、较高BMI(P < .001)、黑人(P < .001)或其他种族(P = .002)、吸烟状态(P < .001)、较大乳房体积(P = .002)、未接受化疗(P = .004)、接受瘤床加量(P < .001)及非教学中心治疗预测乳腺疼痛。
  • 常规分割组中,年轻年龄(P < .001)、较高BMI(P = .003)、黑人(P < .001)或其他种族(P = .002)、糖尿病(P = .001)、吸烟状态(P < .001)及较大乳房体积(P < .001)预测乳腺疼痛。

临床怎么用

  • 临床决策时可参考大分割放疗较常规分割放疗急性毒性报告率更低的证据。
  • 对年轻、高BMI、吸烟、较大乳房体积等易感患者加强支持治疗。
  • 关注不同种族间疼痛报告差异,探索可干预因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Understanding acute toxicities after whole-breast radiotherapy is important to inform patients, guide treatment decisions, and target supportive care. We evaluated patient-reported outcomes prospectively collected from a cohort of patients with breast cancer. METHODS: We describe the maximal toxicity reported by 8,711 patients treated between 2012 and 2019 at 27 practices. Multivariable models identified characteristics associated with (1) breast pain, (2) bother from itching, stinging/burning, swelling, or hurting of the treated breast, and (3) fatigue within 7 days of completing whole-breast radiotherapy. RESULTS: Moderate or severe breast pain was reported by 3,233 (37.1%): 1,282 (28.9%) of those receiving hypofractionation and 1,951 (45.7%) of those receiving conventional fractionation. Frequent bother from at least one breast symptom was reported by 4,424 (50.8%): 1,833 (41.3%) after hypofractionation and 2,591 (60.7%) after conventional fractionation. Severe fatigue was reported by 2,008 (23.1%): 843 (19.0%) after hypofractionation and 1,165 (27.3%) after conventional fractionation. Among patients receiving hypofractionated radiotherapy, younger age (P < .001), higher body mass index (BMI; P < .001), Black (P < .001) or other race (P = .002), smoking status (P < .001), larger breast volume (P = .002), lack of chemotherapy receipt (P = .004), receipt of boost treatment (P < .001), and treatment at a nonteaching center predicted breast pain. Among patients receiving conventionally fractionated radiotherapy, younger age (P < .001), higher BMI (P = .003), Black (P < .001) or other race (P = .002), diabetes (P = .001), smoking status (P < .001), and larger breast volume (P < .001) predicted breast pain. CONCLUSION: In this large observational data set, substantial differences existed according to radiotherapy dose fractionation. Race-related differences in pain existed despite controlling for multiple other factors; additional research is needed to understand what drives these differences to target potentially modifiable factors. Intensifying supportive care may be appropriate for subgroups identified as being vulnerable to greater toxicity.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Jagsi R, Griffith KA, Vicini F, et al. Toward Improving Patients' Experiences of Acute Toxicity From Breast Radiotherapy: Insights From the Analysis of Patient-Reported Outcomes in a Large Multicenter Cohort. J Clin Oncol. 2020. PMID: 32986529. doi:10.1200/JCO.20.01703

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。